{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:34:56Z","timestamp":1777692896641,"version":"3.51.4"},"posted":{"date-parts":[[2026,1,5]]},"group-title":"Systems Biology","reference-count":105,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["T32 AI007528"],"award-info":[{"award-number":["T32 AI007528"]}]},{"name":"NIH","award":["R01 AI50684"],"award-info":[{"award-number":["R01 AI50684"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Tuberculosis (TB) remains a global health concern, as\n                  <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                  (Mtb) currently infects a quarter of the world\u2019s population. Though many TB patients sterilize infection with short-course treatment, regimens shorter than 4 months risk post-treatment, potentially facilitating drug resistance. Granulomas are spatially-heterogeneous hallmark immune structures that form during TB, comprising immune cells and\n                  <jats:italic>caseum<\/jats:italic>\n                  , necrotic tissue that can trap Mtb in a non-replicating state. Two mechanisms causing relapse have been hypothesized:\n                  <jats:italic>persistence<\/jats:italic>\n                  , where treatment kills all replicating Mtb, and relapse follows once Mtb trapped within caseum returns to a replicative niche; and\n                  <jats:italic>threshold<\/jats:italic>\n                  , where replicating Mtb remain alive below detectable levels. Typically, clinical relapse is described as TB recurrence &lt;2 years after a misdiagnosis of cure upon treatment completion (MDxC). Comparatively, many experimental models cannot screen for cure and examine relapse \u223c2-months after treatment completion. Capacity to untangle these considerations\n                  <jats:italic>in vivo<\/jats:italic>\n                  are limited. Here, we examine the impact of study design (e.g., cure screening) on mechanisms underpinning reported instances of relapse using our computational model capturing whole-host Mtb infection dynamics,\n                  <jats:italic>HostSim<\/jats:italic>\n                  . Simulations uncover rates of reported relapse depending on whether hosts are screened for cure upon treatment completion. If not screened, then relapse is likely driven by incomplete sterilization of replicating bacteria; whereas cure-screened relapse is most likely to be caused by gradual expansion of non-replicating Mtb from within caseum into cellular areas of a granuloma. This suggests that TB patients that relapse after MDxC may best be treated with caseum-penetrating antibiotics such as rifamycin-class antibiotics.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>Importance<\/jats:title>\n                  <jats:p>Incomplete treatment of TB leads to risks relapse, which may occur years later. The threat of relapse is the main reason TB treatment takes 4-9 months. Predictors of relapse are not well-defined given variability in technical definitions of relapse and nuances of study designs. Here, we simulate both clinical and experimental relapse studies, including multiple diagnostic tests and relapse definitions, using biologically-based computation. We find that two hypothesized types of relapse that each potentially require a different treatment strategy are simultaneously at play. Simulations suggest that relapse after a \u201ccure\u201d diagnosis (most clinical studies) is caused by reactivation of non-replicating bacteria hidden from treatment within necrotic granuloma tissue or other sites, whereas experiments that cannot test for cure post-treatment are likely to report relapse caused by incomplete sterilization of replicating Mtb. Predictions depend on the currently unclear relationship between bacterial burden and clinical symptoms.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.01.04.697520","type":"posted-content","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:15:22Z","timestamp":1767629722000},"source":"Crossref","is-referenced-by-count":0,"title":["Cure-screening predicts mechanism of post-antibiotic relapse in Tuberculosis"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3583-6097","authenticated-orcid":false,"given":"Christian T.","family":"Michael","sequence":"first","affiliation":[{"name":"Kirschner lab, Department of Microbiology & Immunology, University of Michigan - Michigan Medicine, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maral","family":"Budak","sequence":"additional","affiliation":[{"name":"Kirschner lab, Department of Microbiology & Immunology, University of Michigan - Michigan Medicine, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5169-3714","authenticated-orcid":false,"given":"Philana Ling","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, UPMC Children\u2019s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Kirschner","sequence":"additional","affiliation":[{"name":"Kirschner lab, Department of Microbiology & Immunology, University of Michigan - Michigan Medicine, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2026042902100503000_2026.01.04.697520v2.1","unstructured":"Global Tuberculosis Report 2024. (World Health Organization, Geneva, 2024)."},{"key":"2026042902100503000_2026.01.04.697520v2.2","unstructured":"CDC. Provisional 2025 Tuberculosis Data, United States. Tuberculosis Data https:\/\/www.cdc.gov\/tb-data\/aboutprovisionaldata\/2025-provisional-data.html (2026)."},{"key":"2026042902100503000_2026.01.04.697520v2.3","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.69"},{"key":"2026042902100503000_2026.01.04.697520v2.4","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800993"},{"key":"2026042902100503000_2026.01.04.697520v2.5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005739"},{"key":"2026042902100503000_2026.01.04.697520v2.6","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00010-14"},{"key":"2026042902100503000_2026.01.04.697520v2.7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2213-2600(14)70031-1","article-title":"Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis","volume":"2","year":"2014","journal-title":"Lancet Respir. Med"},{"key":"2026042902100503000_2026.01.04.697520v2.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202410-2096ST"},{"key":"2026042902100503000_2026.01.04.697520v2.9","unstructured":"WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, 2022 Update. (World Health Organization, Geneva, 2022)."},{"key":"2026042902100503000_2026.01.04.697520v2.10","unstructured":"Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management. (World Health Organization, Global TB Programme, Geneva, Switzerland, 2018)."},{"key":"2026042902100503000_2026.01.04.697520v2.11","unstructured":"World Health Organization. Implementing the End TB Strategy: The Essentials, 2022 Update. (Geneva, 2022)."},{"key":"2026042902100503000_2026.01.04.697520v2.12","doi-asserted-by":"crossref","unstructured":"Goletti, D. et al. Can we predict tuberculosis cure? What tools are available? Eur. Respir. J. 52, (2018).","DOI":"10.1183\/13993003.01089-2018"},{"key":"2026042902100503000_2026.01.04.697520v2.13","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/infdis\/jiy712","article-title":"Remembering the Host in Tuberculosis Drug Development","volume":"219","year":"2019","journal-title":"J. Infect. Dis"},{"key":"2026042902100503000_2026.01.04.697520v2.14","doi-asserted-by":"crossref","unstructured":"Danchik, C. , Wang, S. & Karakousis, P. C. Targeting the Mycobacterium tuberculosis Stringent Response as a Strategy for Shortening Tuberculosis Treatment. Front. Microbiol. 12, (2021).","DOI":"10.3389\/fmicb.2021.744167"},{"key":"2026042902100503000_2026.01.04.697520v2.15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/infdis\/jiae477","article-title":"Respiratory Isolation for Tuberculosis: A Historical Perspective","volume":"231","year":"2025","journal-title":"J. Infect. Dis"},{"key":"2026042902100503000_2026.01.04.697520v2.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715849"},{"key":"2026042902100503000_2026.01.04.697520v2.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008632"},{"key":"2026042902100503000_2026.01.04.697520v2.18","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3412"},{"key":"2026042902100503000_2026.01.04.697520v2.19","doi-asserted-by":"crossref","first-page":"e1013033","DOI":"10.1371\/journal.pcbi.1013033","article-title":"Distinguishing multiple roles of T cell and macrophage involvement in determining lymph node fates during Mycobacterium tuberculosis infection","volume":"21","year":"2025","journal-title":"PLOS Comput. Biol"},{"key":"2026042902100503000_2026.01.04.697520v2.20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.18683\/germs.2021.1266","article-title":"Hepatic tuberculosis: myriad of hues","volume":"11","year":"2021","journal-title":"GERMS"},{"key":"2026042902100503000_2026.01.04.697520v2.21","doi-asserted-by":"publisher","DOI":"10.1038\/nri3211"},{"key":"2026042902100503000_2026.01.04.697520v2.22","doi-asserted-by":"publisher","DOI":"10.3791\/55559"},{"key":"2026042902100503000_2026.01.04.697520v2.23","doi-asserted-by":"crossref","first-page":"e1010823","DOI":"10.1371\/journal.pcbi.1010823","article-title":"Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens","volume":"19","year":"2023","journal-title":"PLoS Comput. Biol"},{"key":"2026042902100503000_2026.01.04.697520v2.24","doi-asserted-by":"crossref","unstructured":"Zhan, L. , Tang, J. , Sun, M. & Qin, C. Animal Models for Tuberculosis in Translational and Precision Medicine. Front. Microbiol. 8, (2017).","DOI":"10.3389\/fmicb.2017.00717"},{"key":"2026042902100503000_2026.01.04.697520v2.25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav2104"},{"key":"2026042902100503000_2026.01.04.697520v2.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0207-4"},{"key":"2026042902100503000_2026.01.04.697520v2.27","unstructured":"Examination of Clinical Trial Costs and Barriers for Drug Development. ASPE http:\/\/aspe.hhs.gov\/reports\/examination-clinical-trial-costs-barriers-drug-development-0 (2014)."},{"key":"2026042902100503000_2026.01.04.697520v2.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1472-9792(02)00059-8"},{"key":"2026042902100503000_2026.01.04.697520v2.29","first-page":"e00177","article-title":"Characterizing PET CT patterns and bacterial dissemination features of tuberculosis relapse in the macaque model","volume":"93","year":"2025","journal-title":"Infect. Immun"},{"key":"2026042902100503000_2026.01.04.697520v2.30","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.10.5831-5844.2003"},{"key":"2026042902100503000_2026.01.04.697520v2.31","doi-asserted-by":"crossref","unstructured":"Xu, J. et al. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Antimicrob Agents Chemother 63, (2019).","DOI":"10.1128\/AAC.00021-19"},{"key":"2026042902100503000_2026.01.04.697520v2.32","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00913-17"},{"key":"2026042902100503000_2026.01.04.697520v2.33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01691-15"},{"key":"2026042902100503000_2026.01.04.697520v2.34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-15"},{"key":"2026042902100503000_2026.01.04.697520v2.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00607-8"},{"key":"2026042902100503000_2026.01.04.697520v2.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"2026042902100503000_2026.01.04.697520v2.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117166"},{"key":"2026042902100503000_2026.01.04.697520v2.38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ911"},{"key":"2026042902100503000_2026.01.04.697520v2.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09742-8"},{"key":"2026042902100503000_2026.01.04.697520v2.40","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1186\/s12879-025-11224-7","article-title":"Time to a tuberculosis treatment cure and its predictors among tuberculosis patients at public health facilities in Arba minch town, South Ethiopia: A retrospective cohort study","volume":"25","year":"2025","journal-title":"BMC Infect. Dis"},{"key":"2026042902100503000_2026.01.04.697520v2.41","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200807-1152OC"},{"key":"2026042902100503000_2026.01.04.697520v2.42","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4177"},{"key":"2026042902100503000_2026.01.04.697520v2.43","first-page":"27","article-title":"SHORTENING SHORT COURSE CHEMOTHERAPY: A RANDOMISED CLINICAL TRIAL FOR TREATMENT OF SMEAR POSITIVE PULMONARY TUBERCULOSIS WITH REGIMENS USING OFLOXACIN IN THE INTENSIVE PHASE","volume":"49","year":"2002","journal-title":"Ind. J Tub"},{"key":"2026042902100503000_2026.01.04.697520v2.44","doi-asserted-by":"crossref","unstructured":"Carvalho, A. C. C. et al. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. Front. Immunol. 12, (2021).","DOI":"10.3389\/fimmu.2021.661934"},{"key":"2026042902100503000_2026.01.04.697520v2.45","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202006-2394PP"},{"key":"2026042902100503000_2026.01.04.697520v2.46","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00592-09"},{"key":"2026042902100503000_2026.01.04.697520v2.47","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01599-13"},{"key":"2026042902100503000_2026.01.04.697520v2.48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903856"},{"key":"2026042902100503000_2026.01.04.697520v2.49","doi-asserted-by":"publisher","DOI":"10.1038\/nature09247"},{"key":"2026042902100503000_2026.01.04.697520v2.50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.3.1951"},{"key":"2026042902100503000_2026.01.04.697520v2.51","doi-asserted-by":"crossref","unstructured":"Selvavinayagam, S. T. et al. Clinical laboratory analytes and platelet-associated parameters as surrogate markers of subclinical inflammation in latent tuberculosis infection. Front. Immunol. 16, (2025).","DOI":"10.3389\/fimmu.2025.1662454"},{"key":"2026042902100503000_2026.01.04.697520v2.52","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration & Center for Drug Evaluation and Research. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. (2005)."},{"key":"2026042902100503000_2026.01.04.697520v2.53","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600751104"},{"key":"2026042902100503000_2026.01.04.697520v2.54","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-015-0538-9"},{"key":"2026042902100503000_2026.01.04.697520v2.55","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.019513"},{"key":"2026042902100503000_2026.01.04.697520v2.56","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018564"},{"key":"2026042902100503000_2026.01.04.697520v2.57","first-page":"e01793","article-title":"Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database","volume":"66","year":"2022","journal-title":"Antimicrob. Agents Chemother"},{"key":"2026042902100503000_2026.01.04.697520v2.58","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00531-12"},{"key":"2026042902100503000_2026.01.04.697520v2.59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121497109"},{"key":"2026042902100503000_2026.01.04.697520v2.60","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix247"},{"key":"2026042902100503000_2026.01.04.697520v2.61","doi-asserted-by":"crossref","first-page":"112176","DOI":"10.1016\/j.jtbi.2025.112176","article-title":"Rankings of tuberculosis antibiotic treatment regimens are sensitive to spatial scale, detection limit, and initial host bacterial burden","volume":"611","year":"2025","journal-title":"J. Theor. Biol"},{"key":"2026042902100503000_2026.01.04.697520v2.62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84827-0"},{"key":"2026042902100503000_2026.01.04.697520v2.63","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu186"},{"key":"2026042902100503000_2026.01.04.697520v2.64","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tube.2017.01.007","article-title":"Recurrent tuberculosis in an urban area in China: Relapse or exogenous reinfection?","volume":"103","year":"2017","journal-title":"Tuberculosis"},{"key":"2026042902100503000_2026.01.04.697520v2.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2022.111042"},{"key":"2026042902100503000_2026.01.04.697520v2.66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24516-8"},{"key":"2026042902100503000_2026.01.04.697520v2.67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004603"},{"key":"2026042902100503000_2026.01.04.697520v2.68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004804"},{"key":"2026042902100503000_2026.01.04.697520v2.69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007305"},{"key":"2026042902100503000_2026.01.04.697520v2.70","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41541-019-0113-9","article-title":"Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques","volume":"4","year":"2019","journal-title":"NPJ Vaccines"},{"key":"2026042902100503000_2026.01.04.697520v2.71","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201710-2102OC"},{"key":"2026042902100503000_2026.01.04.697520v2.72","unstructured":"Resoluci\u00f3n Ministerial N.\u00b0 715-2013-MINSA. https:\/\/www.gob.pe\/institucion\/minsa\/normas-legales\/198713-715-2013-minsa."},{"key":"2026042902100503000_2026.01.04.697520v2.73","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix039"},{"key":"2026042902100503000_2026.01.04.697520v2.74","doi-asserted-by":"crossref","unstructured":"Budak, M. et al. GEODE: an in silico tool that translates in vitro to in vivo predictions of tuberculosis antibiotic combination efficacy. Front. Pharmacol. 16, (2025).","DOI":"10.3389\/fphar.2025.1639673"},{"key":"2026042902100503000_2026.01.04.697520v2.75","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-015-0221-8"},{"key":"2026042902100503000_2026.01.04.697520v2.76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2026042902100503000_2026.01.04.697520v2.77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.712457"},{"key":"2026042902100503000_2026.01.04.697520v2.78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000778"},{"key":"2026042902100503000_2026.01.04.697520v2.79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103298"},{"key":"2026042902100503000_2026.01.04.697520v2.80","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5270.1884"},{"key":"2026042902100503000_2026.01.04.697520v2.81","doi-asserted-by":"crossref","unstructured":"Kirschner, D. & Webb, G. F. Immunotherapy of HIV-1 Infection. (1997).","DOI":"10.1080\/10273669708833004"},{"key":"2026042902100503000_2026.01.04.697520v2.82","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.7.4296"},{"key":"2026042902100503000_2026.01.04.697520v2.83","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1021\/acsinfecdis.6b00051","article-title":"Prediction of Drug Penetration in Tuberculosis Lesions","volume":"2","year":"2016","journal-title":"ACS Infect Dis"},{"key":"2026042902100503000_2026.01.04.697520v2.84","first-page":"189","article-title":"Rapid Diagnosis of Recurrent Paucibacillary Tuberculosis","volume":"7","year":"2022","journal-title":"Pathog. Immun"},{"key":"2026042902100503000_2026.01.04.697520v2.85","doi-asserted-by":"crossref","unstructured":"Sarathy, J. P. et al. Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum. Antimicrob Agents Chemother 62, (2018).","DOI":"10.1128\/AAC.02266-17"},{"key":"2026042902100503000_2026.01.04.697520v2.86","unstructured":"Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. https:\/\/www.who.int\/publications\/i\/item\/9789241550000."},{"key":"2026042902100503000_2026.01.04.697520v2.87","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3937"},{"key":"2026042902100503000_2026.01.04.697520v2.88","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Progress of anti-tuberculosis drug targets and novel therapeutic strategies. Front. Microbiol. 16, (2025).","DOI":"10.3389\/fmicb.2025.1637254"},{"key":"2026042902100503000_2026.01.04.697520v2.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2010.07.004"},{"key":"2026042902100503000_2026.01.04.697520v2.90","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00414-06"},{"key":"2026042902100503000_2026.01.04.697520v2.91","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30148-1"},{"key":"2026042902100503000_2026.01.04.697520v2.92","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu574"},{"key":"2026042902100503000_2026.01.04.697520v2.93","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.12-1-40"},{"key":"2026042902100503000_2026.01.04.697520v2.94","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01780-07"},{"key":"2026042902100503000_2026.01.04.697520v2.95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162220"},{"key":"2026042902100503000_2026.01.04.697520v2.96","doi-asserted-by":"crossref","first-page":"e1012138","DOI":"10.1371\/journal.pcbi.1012138","article-title":"Optimal control of agent-based models via surrogate modeling","volume":"21","year":"2025","journal-title":"PLOS Comput. Biol"},{"key":"2026042902100503000_2026.01.04.697520v2.97","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.31.596692"},{"key":"2026042902100503000_2026.01.04.697520v2.98","doi-asserted-by":"crossref","first-page":"928387","DOI":"10.3389\/fsysb.2022.928387","article-title":"Drug Development Digital Twins for Drug Discovery, Testing and Repurposing: A Schema for Requirements and Development","volume":"2","year":"2022","journal-title":"Front. Syst. Biol"},{"key":"2026042902100503000_2026.01.04.697520v2.99","doi-asserted-by":"publisher","DOI":"10.1101\/2023.11.13.566861"},{"key":"2026042902100503000_2026.01.04.697520v2.100","doi-asserted-by":"crossref","unstructured":"Michael, C. T. , Almohri, S. A. , Linderman, J. J. & Kirschner, D. E. A framework for multi-scale intervention modeling: virtual cohorts, virtual clinical trials, and model-to-model comparisons. Front. Syst. Biol. 3, (2024).","DOI":"10.3389\/fsysb.2023.1283341"},{"key":"2026042902100503000_2026.01.04.697520v2.101","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00277-13"},{"key":"2026042902100503000_2026.01.04.697520v2.102","doi-asserted-by":"crossref","unstructured":"Steingart, K. R. et al. Xpert\u00ae MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults - Steingart, KR - 2014 | Cochrane Library. https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD009593.pub3\/information.","DOI":"10.1002\/14651858.CD009593.pub3"},{"key":"2026042902100503000_2026.01.04.697520v2.103","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.7.4195-4201.2001"},{"key":"2026042902100503000_2026.01.04.697520v2.104","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw566"},{"key":"2026042902100503000_2026.01.04.697520v2.105","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/psp4.13117","article-title":"A systematic efficacy analysis of tuberculosis treatment with BPaL-containing regimens using a multiscale modeling approach","volume":"13","year":"2024","journal-title":"CPT Pharmacomet. Syst. Pharmacol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.01.04.697520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:11:20Z","timestamp":1777453880000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.01.04.697520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":105,"URL":"https:\/\/doi.org\/10.64898\/2026.01.04.697520","relation":{},"subject":[],"published":{"date-parts":[[2026,1,5]]},"subtype":"preprint"}}